DBV Technologies Asset Resilience Ratio
DBV Technologies asset resilience ratio. DBV Technologies (DBVT) has an Asset Resilience Ratio of 0.00% as of December 2019. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See DBVT defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of DBV Technologies (2013–2023)
Asset resilience ratio of DBV Technologies from 2013 to 2023. This chart shows how DBV Technologies's Asset Resilience Ratio has changed over time. Read debt load of DBV Technologies for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down DBV Technologies's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of DBV Technologies.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: DBV Technologies maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
DBV Technologies Industry Peers by Asset Resilience Ratio
Compare DBV Technologies's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
DBV Technologies Asset Resilience Ratio by Year (2013–2023)
DBV Technologies asset resilience ratio by year from 2013 to 2023. The table below shows the annual Asset Resilience Ratio data for DBV Technologies.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | -7.32% | $-13.39 Million | $182.99 Million | -- |
| 2019-12-31 | 0.00% | $0.00 | $271.73 Million | -- |
| 2018-12-31 | 23.18% | $54.41 Million | $234.76 Million | -26.43pp |
| 2017-12-31 | 49.61% | $124.17 Million | $250.28 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $317.16 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $409.53 Million | -- |
| 2013-12-31 | 0.41% | $345.41K | $84.80 Million | -- |
About DBV Technologies
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobu… Read more